Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression
Source: Article title. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression
Study design awaiting verification · PLOS One · 2025
Original publication title
Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression
© 2025 Nasri et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Acute myeloid leukemia (AML) is a malignant disorder characterized by the accumulation of immature myeloid cells which can be developed and exacerbated through inflammation. Interferon-β (IFN-β) and vitamin D (Vit D) are known for their immunomodulatory and anti-proliferative effects. Key molecules like IL-1β, Gal-9, β-catenin, and NF-κB play important roles in AML progression. This study examines the effects of IFN-β alone and in combination with Vit D on U937 cell proliferation and the regulation of these key molecules.
Source: BackgroundAbstract: What methods does the paper describe?
Cell counting kit-8 (CCK-8) was applied to assess the effect of IFN-β and Vit D on U937 cells proliferation. Real-time PCR was carried out to evaluate the impact of IFN-β and Vit D on IL-1β, IL-10, Gal-9, β-catenin, and NF-κB genes. ELISA was performed to estimate the protein levels of IL-1β and IL-10. Western-blotting was applied to evaluate the NF-κB signaling pathway.
Source: MethodsAbstract: Results
The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. IL-1β gene expression was reduced following either IFN-β or Vit D treatment, while IL-10 gene expression underwent a gentl increase following treatment with IFN-β, which was in contrast to Vit D treatment. IFN-β in contrast to Vit D decreased Gal-9 gene expression. β-catenin gene expression increased after IFN-β or Vit D treatment. NF-κB gene expression reduced following either IFN-β or Vit D treatment, except for the highest concentration of Vit D.
At protein level, IFN-β and Vit D treatment leads to a reduction of both IL-1β and IL-10 as well as p-NF-κB.
Source: ResultsAbstract: Conclusion
Our findings suggest that IFN-β effectively inhibits U937 cell proliferation and modulates key inflammatory and immune-related molecules involved in AML pathogenesis. These results highlight IFN-β as a promising agent for targeting critical pathways in AML and suggest a modulatory, but less potent role for Vit D.
Source: ConclusionAuthors’ abstract
Background
Acute myeloid leukemia (AML) is a malignant disorder characterized by the accumulation of immature myeloid cells which can be developed and exacerbated through inflammation. Interferon-β (IFN-β) and vitamin D (Vit D) are known for their immunomodulatory and anti-proliferative effects. Key molecules like IL-1β, Gal-9, β-catenin, and NF-κB play important roles in AML progression. This study examines the effects of IFN-β alone and in combination with Vit D on U937 cell proliferation and the regulation of these key molecules.
Methods
Cell counting kit-8 (CCK-8) was applied to assess the effect of IFN-β and Vit D on U937 cells proliferation. Real-time PCR was carried out to evaluate the impact of IFN-β and Vit D on IL-1β, IL-10, Gal-9, β-catenin, and NF-κB genes. ELISA was performed to estimate the protein levels of IL-1β and IL-10. Western-blotting was applied to evaluate the NF-κB signaling pathway.
Results
The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. IL-1β gene expression was reduced following either IFN-β or Vit D treatment, while IL-10 gene expression underwent a gentl increase following treatment with IFN-β, which was in contrast to Vit D treatment. IFN-β in contrast to Vit D decreased Gal-9 gene expression. β-catenin gene expression increased after IFN-β or Vit D treatment. NF-κB gene expression reduced following either IFN-β or Vit D treatment, except for the highest concentration of Vit D.
At protein level, IFN-β and Vit D treatment leads to a reduction of both IL-1β and IL-10 as well as p-NF-κB.
Conclusion
Our findings suggest that IFN-β effectively inhibits U937 cell proliferation and modulates key inflammatory and immune-related molecules involved in AML pathogenesis. These results highlight IFN-β as a promising agent for targeting critical pathways in AML and suggest a modulatory, but less potent role for Vit D.
Publication and source details
Original title: Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression
Farzad Nasri; Hassan Jalaeikhoo; Maryam Dadmanesh; Nafiseh Behranvand; Reza Falak; Negin Hosseini Rouzbahan; Yalda Babaei; Khodayar Ghorban
PLOS One · 2025
* E-mail: kh.ghorban@gmail.comCompeting Interests: The authors have declared that no competing interests exist.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:58:23.446656+00:00
DOI: 10.1371/journal.pone.0330865 · PMC12530539